A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
1. Be 18 years or older and male.
2. Have histologically or cytologically confirmed diagnosis of adenocarcinoma of the
3. Patients without evidence of PSA progression must have clinical or radiographic
evidence of metastatic disease.
4. Must have castrate levels of testosterone (serum testosterone less than 50ng/dl) by
either being on androgen ablation therapy with a luteinizing hormone-releasing
hormone (LHRH) agonist or have had a prior bilateral orchiectomy.
5. Patients must have documented evidence of disease progression: progressive disease
is defined as a minimum of three consecutive elevations in PSA each obtained a
minimum of one week apart with the last value being greater than 2 ng/mL and/or new
metastatic lesions on bone scan (minimum of 2) and/or new or progressive disease on
CT or MRI scan.
6. For patients on an antiandrogen (flutamide, nilutamide, bicalutamide)
1. If given as part of first line therapy or for patients who did respond to
antiandrogen second line therapy, the patient must demonstrate progression of
disease at least 4 weeks beyond discontinuation of such agents to rule out an
antiandrogen withdrawal response.
2. If given as a second line therapy and the patient did not respond or had a
decline in PSA for less than 3 months, it is not required to observe for a
7. Chemotherapy-naïve patients (unlimited prior regimens of hormonal therapy are
8. Have no other malignancy within the past five years, except non-melanoma, skin
9. Have recovered from acute toxicities of prior treatment:
1. Greater than or equal to 4 weeks must have elapsed since receiving hormonal
therapy (except for chronic non-investigational gonadotropin releasing hormone
analogs or other primary androgen suppressive therapy which are required),
biologic agents or any investigational agent (palliative bisphosphonate therapy
for bone pain can be administered as clinically indicated).
2. Greater than or equal to 4 weeks must have elapsed since receiving any
3. Greater than or equal to 2 weeks must have elapsed since any prior surgery or
granulocyte-stimulating growth factor therapy.
10. Have the following hematology levels at Baseline:
1. Absolute Neutrophil Count (ANC) greater than or equal to1,500 x 106 cells/L
2. Platelets greater than or equal to 100 x 109 cells/L
3. Hemoglobin greater than or equal to 9 g/L.
11. Have the following chemistry levels at Baseline:
1. AST (SGOT), ALT (SGPT) less than or equal to 1.5 x ULN
2. Total bilirubin less than or equal to 1.5 ULN
3. Creatinine less than or equal to 1.5 ULN; or 24-hour creatinine clearance
greater than 60 mL/min
4. Normal serum electrolytes and magnesium levels
12. Have a life expectancy of greater than or equal to 12 weeks.
13. Have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.
14. Patient or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee (EC)/Institutional Review Board
(IRB)-approved written informed consent form (ICF) prior to receiving any study
1. Patient has radiographic evidence of active (symptomatic, untreated) intraparenchymal
brain metastases; any meningeal metastases; or asymptomatic untreated
intraparenchymal brain metastases requiring treatment.
2. Patient has received prior chemotherapy for metastatic prostate cancer.
3. Patient has a known infection with human immunodeficiency virus or active viral
4. Patient has active heart disease including myocardial infarction or congestive heart
failure within the previous 6 months, symptomatic coronary artery disease, or
5. Any condition which in the Investigator's opinion deems the patient an unsuitable
candidate to receive study drug (e.g., uncontrolled bleeding or bleeding diathesis).
6. Any active infection requiring parenteral or oral antibiotics.
7. Patient treated with any of the following:
1. Taxol, Taxotere or Abraxane for prostate cancer or any prior malignancy
2. Concurrent radiation therapy (except for palliative radiotherapy for symptomatic
bone metastasis which can be administered as clinically indicated)
8. Patient has pre-existing peripheral neuropathy of Grade greater than 1 based on the
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).